Journal article
Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists Guideline
Journal of clinical oncology, Vol.41(10), pp.1943-1948
04/01/2023
DOI: 10.1200/JCO.22.02462
PMID: 36603179
Abstract
PURPOSE The College of American Pathologists (CAP) has developed a guideline on testing for mismatch repair (MMR) and microsatellite instability (MSI) for patients considered for immune checkpoint inhibitor therapy. ASCO has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. METHODS The CAP guideline was reviewed for developmental rigor by methodologists. An ASCO Endorsement Panel subsequently reviewed the content and the recommendations. RESULTS The ASCO Endorsement Panel determined that the recommendations from the CAP guideline, published on August 3, 2022, are clear, thorough, and based on the most relevant scientific evidence. ASCO endorses Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: Guideline From the College of American Pathologists in Collaboration With the Association for Molecular Pathology and Fight Colorectal Cancer. RECOMMENDATIONS Within the guideline, MMR immunohistochemistry (IHC), MSI polymerase chain reaction, and MSI next-generation sequencing are all recommended testing options for colorectal cancer, MMR-IHC and MSI-polymerase chain reaction for gastroesophageal and small bowel cancer, and only MMR-IHC for endometrial cancer. No recommendation in favor of any testing method over another could be made for any other cancer. Tumor mutational burden was not recommended as a surrogate for DNA MMR deficiency. If MMR deficiency consistent with Lynch syndrome is detected, it should be communicated to the treating physician. Additional information is available at www.asco.org/molecular-testing-and-biomarkers-guidelines .
Details
- Title: Subtitle
- Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists Guideline
- Creators
- Praveen Vikas - University of IowaHans Messersmith - American Society of Clinical OncologyCarolyn Compton - Mayo Clinic in ArizonaLynette Sholl - Brigham and Women's HospitalRussell R. Broaddus - University of North Carolina at Chapel HillAnjee Davis - Fight Colorectal Cancer, Springfield, MO.Maria Estevez-Diz - Instituto do Câncer do Estado de São PauloRohan Garje - Baptist Health South FloridaPanagiotis A. Konstantinopoulos - Dana-Farber Cancer InstituteAliza Leiser - Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.Anne M. Mills - University of VirginiaBarbara Norquist - University of Washington Medical CenterMichael J. Overman - The University of Texas MD Anderson Cancer CenterDavendra Sohal - University of CincinnatiRichard C. Turkington - Queen's University BelfastTyler Johnson - Stanford University
- Resource Type
- Journal article
- Publication Details
- Journal of clinical oncology, Vol.41(10), pp.1943-1948
- DOI
- 10.1200/JCO.22.02462
- PMID
- 36603179
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Language
- English
- Electronic publication date
- 01/05/2023
- Date published
- 04/01/2023
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984363437502771
Metrics
12 Record Views